Bevacizumab
CAS 216974-75-3 2 FDA-DMF suppliersBiologic
Overview
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to and neutralizing vascular endothelial growth factor A (VEGF-A). It is used primarily in the treatment of various cancers and certain ocular diseases.
Therapeutic areas
OncologyOphthalmology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.